Outcome of the Board Meeting held on July 28, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenotech Laboratories' Board approved its unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell to Rs 863.91 lakhs from Rs 889.49 lakhs in the same quarter last year, a decline of about 2.9%. Total income was largely flat at Rs 1,023.16 lakhs, but expenses rose roughly 9% to Rs 895.48 lakhs, pushing profit before tax down to Rs 127.68 lakhs (from Rs 204.55 lakhs) and profit after tax down to Rs 98.96 lakhs (from Rs 128.97 lakhs). EPS stood at Rs 0.16 versus Rs 0.21 in Q1 FY25. The statutory auditor PKF Sridhar & Santhanam LLP completed its two permissible terms, and M/s. G S K A & Co. has been appointed as the new auditor for a 5-year term subject to shareholder approval. The 36th AGM is scheduled for September 26, 2025 via video conferencing.
Weak quarter for shareholders – lower revenue combined with rising expenses (mainly employee costs and depreciation) significantly compressed margins and pushed profits down by roughly 23%. The auditor change is a routine rotation after PKF completed its allowed tenure and is unlikely to be disruptive. Watch for any commentary on the ongoing Rs 422.10 lakh export-related provision.